Prioritizing relationship with Trump and Kennedy, BIO and PhRMA do not protest firings

Pharmaceutical and biotech industry associations, which have embraced the Trump administration, have avoided criticizing the recent mass firings at government public health agencies, including at FDA, NIH, CDC and CMS.

PhRMA and BIO have prioritized maintaining cordial relations with President Donald Trump and HHS Secretary Robert F. Kennedy Jr. Leaders of the biopharmaceutical trade associations, along with pharma CEOs, worry that publicly opposing the cuts could provoke retribution from Trump and Kennedy, jeopardizing the industry’s efforts to secure White House support for changes to the Medicare drug price negotiation program, restrictions on PBM business practices, and FDA reforms...